




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 401/06, 401/14, 409/14, 405/14, 213/38, 471/10, 491/10, 495/10, A61K 31/44		A1	(11) International Publication Number: WO 00/14086
			(43) International Publication Date: 16 March 2000 (16.03.00)
(21) International Application Number: PCT/US99/01365		(74) Agents: CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds P.C., Two Militia Drive, Lexington, MA 02421 (US).	
(22) International Filing Date: 21 January 1999 (21.01.99)			
(30) Priority Data: 09/148,236 4 September 1998 (04.09.98) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/148,236 (CIP) Filed on 4 September 1998 (04.09.98)			
(71) Applicants (for all designated States except US): LEUKOSITE, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US). KYOWA HAKKO KOGYO CO., LTD. [JP/JP]; 6-1 Ohtemachi, 1-chome, Chiyoda-ku, Tokyo 100 (JP).			
(72) Inventors; and		Published <i>With international search report.</i>	
(75) Inventors/Applicants (for US only): LULY, Jay, R. [US/US]; 24 Damien Road, Wellesley, MA 02481 (US). NAKASATO, Yoshisuke [JP/JP]; 80-1, Shimotogari, Nagazumi-cho, Sunto-gun, Shizuoka 411 (JP). OHSHIMA, Etsuo [JP/JP]; 234-16-202, Honjuku, Nagazumi-cho, Sunto-gun, Shizuoka 411 (JP).			

(54) Title: CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR

(57) Abstract

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by structural formula (A) and physiologically acceptable salts thereof.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

CHEMOKINE RECEPTOR ANTAGONISTS

5 AND METHODS OF USE THEREFOR

RELATED APPLICATION

This application is a continuation-in-part of U.S. Serial NO. 09/148,236, filed September 4, 1998, the entire teachings of which are incorporated herein by reference.

10 BACKGROUND OF THE INVENTION

Chemoattractant cytokines or chemokines are a family of proinflammatory mediators that promote recruitment and activation of multiple lineages of leukocytes and lymphocytes. They can be released by many kinds of tissue 15 cells after activation. Continuous release of chemokines at sites of inflammation mediates the ongoing migration of effector cells in chronic inflammation. The chemokines characterized to date are related in primary structure. They share four conserved cysteines, which form disulfide 20 bonds. Based upon this conserved cysteine motif, the family is divided into two main branches, designated as the C-X-C chemokines (α -chemokines), and the C-C chemokines

-2-

(β -chemokines), in which the first two conserved cysteines are separated by an intervening residue, or adjacent respectively (Baggiolini, M. and Dahinden, C. A., *Immunology Today*, 15:127-133 (1994)).

- 5 The C-X-C chemokines include a number of potent chemoattractants and activators of neutrophils, such as interleukin 8 (IL-8), PF4 and neutrophil-activating peptide-2 (NAP-2). The C-C chemokines include RANTES (Regulated on Activation, Normal T Expressed and Secreted), the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β), eotaxin and human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2, MCP-3), which have been characterized as chemoattractants and activators of monocytes or lymphocytes but do not appear to be chemoattractants for neutrophils. Chemokines, such as RANTES and MIP-1 α , have been implicated in a wide range of human acute and chronic inflammatory diseases including respiratory diseases, such as asthma and allergic disorders.
- 10 The chemokine receptors are members of a superfamily of G protein-coupled receptors (GPCR) which share structural features that reflect a common mechanism of action of signal transduction (Gerard, C. and Gerard, N.P., *Annu Rev. Immunol.*, 12:775-808 (1994); Gerard, C. and Gerard, N. P., *Curr. Opin. Immunol.*, 6:140-145 (1994)). Conserved features include seven hydrophobic domains spanning the plasma membrane, which are connected by hydrophilic extracellular and intracellular loops. The majority of the primary sequence homology occurs in the hydrophobic transmembrane regions with the hydrophilic
- 15
- 20
- 25
- 30

-3-

regions being more diverse. The first receptor for the C-C chemokines that was cloned and expressed binds the chemokines MIP-1 α and RANTES. Accordingly, this MIP-1 α /RANTES receptor was designated C-C chemokine 5 receptor 1 (also referred to as CCR-1; Neote, K., et al., Cell, 72:415-425 (1993); Horuk, R. et al., WO 94/11504, May 26, 1994; Gao, J.-I. et al., *J. Exp. Med.*, 177:1421-1427 (1993)). Three receptors have been characterized which bind and/or signal in response to RANTES: CCR3 mediates 10 binding and signaling of chemokines including eotaxin, RANTES, and MCP-3 (Ponath et al., *J. Exp. Med.*, 183:2437 (1996)), CCR4 binds chemokines including RANTES, MIP-1 α , and MCP-1 (Power, et al., *J. Biol. Chem.*, 270:19495 (1995)), and CCR5 binds chemokines including MIP-1 α , 15 RANTES, and MIP-1 β (Samson, et al., *Biochem.* 35: 3362-3367 (1996)). RANTES is a chemotactic chemokine for a variety of cell types, including monocytes, eosinophils, and a subset of T-cells. The responses of these different cells may not all be mediated by the same receptor, and it is 20 possible that the receptors CCR1, CCR4 and CCR5 will show some selectivity in receptor distribution and function between leukocyte types, as has already been shown for CCR3 (Ponath et al.). In particular, the ability of RANTES to induce the directed migration of monocytes and a memory 25 population of circulating T-cells (Schall, T. et al., *Nature*, 347:669-71 (1990)) suggests this chemokine and its receptor(s) may play a critical role in chronic inflammatory diseases, since these diseases are characterized by destructive infiltrates of T cells and 30 monocytes.

Many existing drugs have been developed as antagonists of the receptors for biogenic amines, for example, as antagonists of the dopamine and histamine receptors. No successful antagonists have yet been developed to the 5 receptors for the larger proteins such as chemokines and C5a. Small molecule antagonists of the interaction between C-C chemokine receptors and their ligands, including RANTES and MIP-1 α , would provide compounds useful for inhibiting harmful inflammatory processes "triggered" by receptor 10 ligand interaction, as well as valuable tools for the investigation of receptor-ligand interactions.

SUMMARY OF THE INVENTION

It has now been found that a class of small organic 15 molecules are antagonists of chemokine receptor function and can inhibit leukocyte activation and/or recruitment. An antagonist of chemokine receptor function is a molecule which can inhibit the binding and/or activation of one or more chemokines, including C-C chemokines such as RANTES, 20 MIP-1 α , MCP-2, MCP-3 and MCP-4 to one or more chemokine receptors on leukocytes and/or other cell types. As a consequence, processes and cellular responses mediated by chemokine receptors can be inhibited with these small 25 organic molecules. Based on this discovery, a method of treating a disease associated with aberrant leukocyte recruitment and/or activation is disclosed as well as a method of treating a disease mediated by chemokine receptor function. The method comprises administering to a subject in need an effective amount of a compound or small organic 30 molecule which is an antagonist of chemokine receptor

-5-

function. Compounds or small organic molecules which have been identified as antagonists of chemokine receptor function are discussed in detail herein below, and can be used for the manufacture of a medicament for treating or 5 for preventing a disease associated with aberrant leukocyte recruitment and/or activation. The invention also relates to the disclosed compounds and small organic molecules for use in treating or preventing a disease associated with aberrant leukocyte recruitment and/or activation. The 10 invention also includes pharmaceutical compositions comprising one or more of the compounds or small organic molecules which have been identified herein as antagonists of chemokine function and a suitable pharmaceutical carrier. The invention further relates to novel compounds 15 which can be used to treat an individual with a disease associated with aberrant leukocyte recruitment and/or activation and methods for their preparation.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic showing the preparation of the 20 compounds represented by Structural Formula (I).

Figure 2 is a schematic showing the preparation of the compounds represented by Compound (VI-b).

Figure 3 is a schematic showing the preparation of the compounds represented by Structural Formula (I)

25 Figure 4 is a schematic showing the preparation of representative compounds of Structural Formula (I), wherein Ar¹ and/or Ar² can be substituted with R¹⁰.

- 6 -

Figure 5 is a schematic showing the preparation of representative compounds of Structural Formula (I), wherein Ar¹ and/or Ar² can be substituted with -(O)_u-(CH₂)_t-COOR²⁰, -(O)_u-(CH₂)_t-OC(O)R²⁰, -(O)_u-(CH₂)_t-C(O)-NR²¹R²² or 5 -(O)_u-(CH₂)_t-NHC(O)O-R²⁰.

Figure 6A-6J show the structures of exemplary compounds of the present invention.

Figure 7 shows the preparation of compounds represented by Structural Formula (I) wherein Ar¹ or Ar² is 10 substituted with R⁴⁰.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to small molecule compounds which are modulators of chemokine receptor function. In a preferred embodiment, the small molecule 15 compounds are antagonists of chemokine receptor function. Accordingly, processes or cellular responses mediated by the binding of a chemokine to a receptor can be inhibited (reduced or prevented, in whole or in part), including leukocyte migration, integrin activation, transient 20 increases in the concentration of intracellular free calcium [Ca⁺⁺]_i, and/or granule release of proinflammatory mediators.

The invention further relates to a method of treatment, including prophylactic and therapeutic 25 treatments, of a disease associated with aberrant leukocyte recruitment and/or activation or mediated by chemokines or chemokine receptor function, including chronic inflammatory disorders characterized by the presence of RANTES, MIP-1 α , MCP-2, MCP-3 and/or MCP-4 responsive T cells, monocytes

-7-

and/or eosinophils, including but not limited to diseases such as arthritis (e.g., rheumatoid arthritis), atherosclerosis, arteriosclerosis, ischemia/reperfusion injury, diabetes mellitus (e.g., type 1 diabetes mellitus),
5 psoriasis, multiple sclerosis, inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, rejection of transplanted organs and tissues (i.e., acute allograft rejection, chronic allograft rejection), graft versus host disease, as well as allergies and asthma. Other diseases
10 associated with aberrant leukocyte recruitment and/or activation which can be treated (including prophylactic treatments) with the methods disclosed herein are inflammatory diseases associated with Human Immunodeficiency Virus (HIV) infection, e.g., AIDS
15 associated encephalitis, AIDS related maculopapular skin eruption, AIDS related interstitial pneumonia, AIDS related enteropathy, AIDS related periportal hepatic inflammation and AIDS related glomerulo nephritis. The method comprises administering to the subject in need of treatment an
20 effective amount of a compound (i.e., one or more compounds) which inhibits chemokine receptor function, inhibits the binding of a chemokine to leukocytes and/or other cell types, and/or which inhibits leukocyte migration to, and/or activation at, sites of inflammation.
25 The invention further relates to methods of antagonizing a chemokine receptor, such as CCRL, in a mammal comprising administering to the mammal a compound as described herein.


According to the method, chemokine-mediated chemotaxis
30 and/or activation of pro-inflammatory cells bearing

-8-

receptors for chemokines can be inhibited. As used herein, "pro-inflammatory cells" includes but is not limited to leukocytes, since chemokine receptors can be expressed on other cell types, such as neurons and epithelial cells.

5 While not wishing to be bound by any particular theory or mechanism, it is believed that compounds of the invention are antagonists of the chemokine receptor CCR1, and that therapeutic benefits derived from the method of the invention are the result of antagonism of CCR1
10 function. Thus, the method and compounds of the invention can be used to treat a medical condition involving cells which express CCR1 on their surface and which respond to signals transduced through CCR1, as well as the specific conditions recited above.

15 In one embodiment, the antagonist of chemokine receptor function is represented by Structural Formula (I):



(I)

and physiologically acceptable salts thereof.

20 Ar^1 is a heteroaryl group, and

-9-

Ar² is a carbocyclic aromatic or heteroaryl group.

n is an integer, such as an integer from one to about four. Preferably, n is one, two or three. More preferably n is two. In alternative embodiments, other aliphatic or 5 aromatic spacer groups (L) can be employed for (CH₂)_n.

M is >NR² or >CR¹R². M is preferably >C(OH)R².

R¹ is -H, -OH, -N₃, halogen, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH, -S-(aliphatic group), -S-(substituted aliphatic group), 10 -OC(O)-(aliphatic group), -O-C(O)-(substituted aliphatic group), -C(O)O-(aliphatic group), -C(O)O-(substituted aliphatic group), -COOH, -CN, -CO-NR³R⁴, -NR³R⁴; or R¹ can be a covalent bond between the ring atom at M and an adjacent carbon atom in the ring which contains M. R¹ is preferably 15 -H or -OH.

R² is -H, -OH, an acyl group, a substituted acyl group, -NR⁵R⁶, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic 20 heterocyclic group or a substituted non-aromatic heterocyclic group. R² is preferably an aromatic group or a substituted aromatic group.


R³, R⁴, R⁵ and R⁶ are independently -H, an acyl group, a substituted acyl group, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic 25 heterocyclic group or a substituted non-aromatic heterocyclic group.

R¹ and R², R³ and R⁴, or R⁵ and R⁶ taken together with 30 the atom to which they are bonded, can alternatively form a

-10-

substituted or unsubstituted non-aromatic carbocyclic or heterocyclic ring.

In embodiments where M is $>CR^1R^2$ and R¹ is a covalent bond between the carbon atom at M and an adjacent carbon atom in the ring which contains M, the antagonist of chemokine function can be represented by Structural Formula 5 (Ia).



(Ia)

10 Ar¹, Ar², n and R² are as described in Structural Formula (I).

Ar¹ and Ar² in Structural Formula (I) can be independently substituted or unsubstituted. Suitable substituents are as described herein below. In one example, Ar¹ and/or Ar² is substituted with 15 - (O)_u - (CH₂)_t - C(O)OR²⁰, - (O)_u - (CH₂)_t - OC(O)R²⁰, - (O)_u - (CH₂)_t - C(O) - NR²¹R²² or - (O)_u - (CH₂)_t - NHC(O) - O - R²⁰. u is zero or one.

-11-


t is an integer, such as an integer from zero to about three. The methylene group, -(CH₂)_t-, can be substituted or unsubstituted.

R²⁰, R²¹ or R²² are independently -H, an aliphatic group, 5 a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group. Alternatively, R²¹ and R²², taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.

10 In one embodiment, Ar¹ is a 3-pyridyl group, Ar² is a carbocyclic aromatic or heteroaromatic group and Ar¹ and Ar² are independently substituted or unsubstituted.


In a preferred embodiment the antagonist of chemokine receptor function is represented by Structural Formula 15 (II), wherein Ar¹ is a 3-pyridyl group, Ar² is a phenyl group and Ar¹ and Ar² are independently substituted or unsubstituted.

-12-



(II)

Preferably Ar^2 in Structural Formula (II) bears a meta substituent, R^{40} , and the antagonist of chemokine receptor
5 function is represented by Structural Formula (III):



(III)

-13-

wherein R⁴⁰ is a substituent as described herein, for example, -OH, halogen, substituted or unsubstituted aliphatic group, substituted or unsubstituted aromatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group, electron withdrawing group,

5

- (O)_u-(CH₂)_t-C(O)OR²⁰, -(O)_u-(CH₂)_t-OC(O)R²⁰,
- (O)_u-(CH₂)_t-C(O)-NR²¹R²² or - (O)_u-(CH₂)_t-NHC(O)-O-R²⁰.

u is zero or one.


10 t is an integer, such as an integer from zero to about three.

R²⁰, R²¹ or R²² are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group. Alternatively, R²¹ and R²², taken together with the 15 nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.

Preferably R⁴⁰ is an aliphatic group, substituted aliphatic group, -O-(aliphatic group) or -O-(substituted 20 aliphatic group). More preferably, R⁴⁰ is -O-alkyl, such as -O-CH₃, -O-C₂H₅, -O-C₃H₇ or -O-C₄H₉.

In another embodiment, the antagonist of chemokine activity is represented by Structural Formula (IV):

-14-



(IV)


and physiologically acceptable salts thereof.

Ar¹, Ar², n and M are as described in Structural

5 Formula (I).

q is an integer, such as an integer from zero to about three, and the ring containing M can be substituted or unsubstituted.

Thus, the antagonist of chemokine function can be
10 represent by, for example, Sturctural Formulas (IVa) - (IVd) :




5 and physiologically acceptable salts thereof, wherein Ar¹,
 Ar², n and M are as described in Structural Formula (IV),


and the ring which contains M is substituted or unsubstituted.

Another embodiment provides novel compounds employed in these methods.

5 The double bond-containing compounds disclosed herein can be obtained as E- and Z-configurational isomers. It is expressly pointed out that the invention includes compounds of the E-configuration and the Z-configuration around the double bond, and a method of treating a subject with
10 compounds of the E-configuration, the Z-configuration, and mixtures thereof. Accordingly, in the structural formulas presented herein, the symbol:



15 is used to represent both E-configuration and the Z-configuration. Preferably Ar¹ and the (CH₂)_n moiety are in the cis configuration. For example, the compounds can have the configuration of:



-17-

It is understood that one configuration can have greater activity than another. The desired configuration can be determined by screening for activity, employing the methods described herein.

5 Additionally, certain compounds of the invention may be obtained as different stereoisomers (e.g., diastereomers and enantiomers). It is pointed out that the invention includes all isomeric forms and racemic mixtures of the disclosed compounds and a method of treating a subject with
10 both pure isomers and mixtures thereof, including racemic mixtures. Again, it is understood that one stereoisomer may be more active than another. The desired isomer can be determined by screening.

Also included in the present invention are
15 physiologically acceptable salts of the compounds represented by Structural Formulas (I) through (IVd). Salts of compounds containing an amine or other basic group can be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride,
20 hydrogen bromide, acetic acid, citric acid, perchloric acid and the like. Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Salts of compounds containing a carboxylic acid or other acidic
25 functional group can be prepared by reacting with a suitable base, for example, a hydroxide base. Salts of acidic functional groups contain a countercation such as sodium, potassium, ammonium, calcium and the like.

As used herein, aliphatic groups include straight
30 chained, branched or cyclic C₁-C₂₀ hydrocarbons which are

completely saturated or which contain one or more units of unsaturation. For example, suitable aliphatic groups include substituted or unsubstituted linear, branched or cyclic C₁-C₂₀ alkyl, alkenyl or alkynyl groups.

5 Aromatic groups include carbocyclic aromatic groups such as phenyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl, and heterocyclic aromatic or heteroaryl groups such as N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 10 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-pyrazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 5-tetrazolyl, 2-oxazolyl, 4-oxazolyl and 5-oxazolyl. Where 15 these rings are fused, for example, to a non-aromatic or aromatic ring, the stated point of attachment can be either of the two fused bonds.

Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or 20 heteroaryl ring is fused to one or more other rings. Examples include tetrahydronaphthyl, 2-benzothienyl, 3-benzothienyl, 2-benzofuranyl, 3-benzofuranyl, 2-indolyl, 3-indolyl, 2-quinolinyl, 3-quinolinyl, 2-benzothiazolyl, 2-benzooxazolyl, 2-benzimidazolyl, 2-quinolinyl, 25 3-quinolinyl, 1-isoquinolinyl, 3-quinolinyl, 1-isoindolyl, 3-isoindolyl, acridinyl, 3-benzisoxazolyl, and the like. Also included within the scope of the term "aromatic group", as it is used herein, is a group in which one or more carbocyclic aromatic rings and/or heteroaryl rings are 30 fused to a cycloalkyl or non-aromatic heterocyclic ring.

The term "non-aromatic ring" includes non-aromatic carbocyclic rings and non-aromatic heterocyclic rings. Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring. The ring can be five, six, seven or eight-membered and/or fused to another ring, such as a cycloalkyl on aromatic ring.

Examples of non-aromatic rings include, for example,

5 3-1H-benzimidazol-2-one, 3-1-alkyl-benzimidazol-2-one,

10 3-1-methyl-benzimidazol-2-one, 2-tetrahydrofuranyl,

 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl,

 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino,

 4-morpholino, 2-thiomorpholino,

 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl,

15 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl,


 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl,

 4-piperidinyl, 4-thiazolidinyl, diazolonyl, N-substituted diazolonyl, 1-phthalimidyl, 1-3-alkyl-phthalimidyl,

 tetrahydronaphthyl, benzocyclopentane, benzocyclohexane,

20 benzoxane, benzopyrrolidine, benzopiperidine, benzoxolane,

 benzothiolane, benzothiane,



-20-

Suitable substituents on an aliphatic group, aromatic group (carbocyclic and heteroaryl), non-aromatic heterocyclic ring or benzyl group include, for example, an electron withdrawing group, a halogen, azido, -CN, -COOH,
5 -OH, -CONR²⁴R²⁵, -NR²⁴R²⁵, -OS(O)₂NR²⁴R²⁵, -S(O)₂NR²⁴R²⁵, -SO₃H,
-S(O)₂NH₂, guanidino, -(O)_u-(CH₂)_t-C(O)OR²⁰,
-(O)_u-(CH₂)_t-OC(O)R²⁰, -(O)_u-(CH₂)_t-C(O)-NR²¹R²²,
-(O)_u-(CH₂)_t-NHC(O)O-R²⁰, -Q-H, -Q-(aliphatic group),
-Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic
10 group), -Q-(substituted aromatic group),
-Q-(CH₂)_p-(substituted or unsubstituted aromatic group)
(p is an integer from 1-5), -Q-(non-aromatic heterocyclic group) or -Q-(CH₂)_p-(non-aromatic heterocyclic group).

R²⁰, R²¹ or R²² are independently -H, an aliphatic group,
15 a substituted aliphatic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or -NHC(O)-O-(non-aromatic heterocyclic group) and wherein R²¹ and R²², taken together with the nitrogen atom
20 to which they are bonded, can form a non-aromatic heterocyclic ring.

t is an integer from zero to about three, and the methylene group, -(CH₂)_t-, can be substituted or unsubstituted.

25 u is zero or one.

Q is -O-, -S-, -S(O)-, -S(O)₂-, -OS(O)₂-, -C(O)-,
-OC(O)-, -C(O)O-, -C(O)C(O)-O-, -O-C(O)C(O)-, -C(O)NH-,
-NHC(O)-, -OC(O)NH-, -NHC(O)O-, -NH-C(O)-NH-, -S(O)₂NH-,
-NHS(O)₂-, -N(R²³)-, -C(NR²³)NHNH-, -NHNHC(NR²³)-, -NR²⁴C(O)-
30 or -NR²⁴S(O)₂-.

-21-

R²³ is -H, an aliphatic group, a benzyl group, an aryl group or non-aromatic heterocyclic group.

R²⁴ and R²⁵ are independently -H, -OH, an aliphatic group, a substituted aliphatic group, a benzyl group, an 5 aryl group or non-aromatic heterocyclic group.

A substituted non-aromatic heterocyclic ring, benzyl group or aromatic group can also have an aliphatic or substituted aliphatic group as a substituent. A substituted aliphatic group can also have an oxo group, 10 epoxy group, non-aromatic heterocyclic ring, benzyl group, substituted benzyl group, aromatic group or substituted aromatic group as a substituent. A substituted non-aromatic heterocyclic ring can also have =O, =S, =NH or =N(aliphatic, aromatic or substituted aromatic group) as a 15 substituent. A substituted aliphatic, substituted aromatic, substituted non-aromatic heterocyclic ring or substituted benzyl group can have more than one substituent.

Acyl groups include substituted and unsubstituted 20 aliphatic carbonyl, aromatic carbonyl, aliphatic sulfonyl and aromatic sulfonyl.

Suitable electron withdrawing groups include, for example, alkylimines, alkylsulfonyl, carboxamido, carboxylic alkyl esters, -CH=NH, -CN, -NO₂, and halogens.

25 A "subject" is preferably a bird or mammal, such as a human, but can also be an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, fowl, pigs, horses, and the like) and laboratory animals (e.g., rats, 30 mice, guinea pigs, and the like).

-22-

An "effective amount" of a compound is an amount which results in the inhibition of one or more processes mediated by the binding of a chemokine to a receptor in a subject with a disease associated with aberrant leukocyte recruitment and/or activation. Examples of such processes include leukocyte migration, integrin activation, transient increases in the concentration of intracellular free calcium $[Ca^{2+}]_i$, and granule release of proinflammatory mediators. Alternatively, an "effective amount" of a compound is a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in the prevention of or a decrease in the symptoms associated with a disease associated with aberrant leukocyte recruitment and/or activation.

The amount of compound administered to the individual will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Typically, an effective amount of the compound can range from about 0.1 mg per day to about 100 mg per day for an adult. Preferably, the dosage ranges from about 1 mg per day to about 100 mg per day. An antagonist of chemokine receptor function can also be administered in combination with one or more additional therapeutic agents, e.g. theophylline, β -adrenergic bronchodilators, corticosteroids, antihistamines, antiallergic agents,

-23-

immunosuppressive agents (e.g., cyclosporin A, FK-506, prednisone, methylprednisolone) and the like.

The compound can be administered by any suitable route, including, for example, orally in capsules, suspensions or 5 tablets or by parenteral administration. Parenteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection. The compound can also be administered orally (e.g., dietary), 10 transdermally, topically, by inhalation (e.g., intrabronchial, intranasal, oral inhalation or intranasal drops), or rectally, depending on the disease or condition to be treated. Oral or parenteral administration are preferred modes of administration.

15 The compound can be administered to the individual in conjunction with an acceptable pharmaceutical or physiological carrier as part of a pharmaceutical composition for treatment of HIV infection, inflammatory disease, or the other diseases discussed above.

20 Formulation of a compound to be administered will vary according to the route of administration selected (e.g., solution, emulsion, capsule). Suitable carriers may contain inert ingredients which do not interact with the compound. Standard pharmaceutical formulation techniques 25 can be employed, such as those described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. Suitable carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about 0.9% mg/ml 30 benzyl alcohol), phosphate-buffered saline, Hank's

-24-

solution, Ringer's-lactate and the like. Methods for encapsulating compositions (such as in a coating of hard gelatin or cyclodextran) are known in the art (Baker, et al., "Controlled Release of Biological Active Agents", John Wiley and Sons, 1986).

The activity of compounds of the present invention can be assessed using suitable assays, such as receptor binding assays and chemotaxis assays. For example, as described in the Exemplification Section, small molecule antagonists of RANTES and MIP-1 α binding have been identified utilizing THP-1 cells which bind RANTES and chemotax in response to RANTES and MIP-1 α as a model for leukocyte chemotaxis. Specifically, a high through-put receptor binding assay, which monitors ^{125}I -RANTES and ^{125}I -MIP-1 α binding to THP-1 cell membranes, was used to identify small molecule antagonists which block binding of RANTES and MIP-1 α . Compounds of the present invention can also be identified by virtue of their ability to inhibit the activation steps triggered by binding of a chemokine to its receptor, such as chemotaxis, integrin activation and granule mediator release. They can also be identified by virtue of their ability to block RANTES and MIP-1 α mediated HL-60, T-cell, peripheral blood mononuclear cell, and eosinophil chemotactic response.

The compounds disclosed herein can be prepared accordingly to the schemes shown in Figures 1 - 5 and 7. The schemes are described in greater detail below.

Figure 1 shows the preparation of compounds represented by Structural Formula (I). L¹ is PPh₃Cl, PPh₃Br, PPh₃I or (EtO)₂P(O), L² is a suitable leaving group such as halogen,

-25-

p-toluene sulfonate, mesylate, alkoxy, and phenoxy; Pg is a suitable protecting group such as tetrahydropyranyl; and the other symbols are as defined above.

In Step 1 of Figure 1, a Wittig reaction is carried out in a solvent such as ether, or tetrahydrofuran (THF) in the presence of a base such as sodium hydride, n-butyl lithium or lithium diisopropylamide (LDA) at 0°C up to the reflux temperature for the solvent used for 5 minutes to 72 h. Compounds represented by Formula II in Figure 1 can be prepared by methods disclosed in J. Med. Chem., 1992 (35) 2074-2084, the entire teachings of which are incorporated herein by reference.

In Step 2 of Figure 1, deprotection is carried out with an acid in a solvent such as methanol at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h. Alternatively, a compound of represented by Formula V in Figure 1 can be prepared directly from step 1 without isolating an intermediate. The reaction mixture obtained after the work up of the reaction described in step 1 can be dissolved in the solvent and reacted with the acid.

In Step 3 of Figure 1, the hydroxy group can be converted to a leaving group by known methods. Compounds represented by Formula VI in Figure 1 can be prepared by methods disclosed in J. Med. Chem., 1992 (35) 2074-2084 and J. Org. Chem., 1977 (42) 353.

In Step 4 of Figure 1, an alkylation reaction is carried out in a solvent such as acetone, methyl ethyl ketone, ethyl acetate, toluene, tetrahydrofuran (THF) or 30 dimethylformamide (DMF) in the presence of a base such as

potassium carbonate or sodium hydride and a catalyst such as an alkali metal iodide at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.

5 Figure 2 shows the preparation of compounds represented by Compound (VI-b). In Step 1 of Figure 2, a Grignard reaction may be carried out in a solvent such as ether, or tetrahydrofuran (THF) at 0°C up to the reflux temperature for the solvent used for 5 minuets to 72 h.

10 Compound VII is available commercially.

In Step 2 of Figure 2, bromination may be carried out with brominate agents such as hydrobromic acid, bromotrimethylsilane or boron tribromide-methyl sulfide complex in a solvent such as acetic acid, dichloromethane 15 or dichloroethane at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.

Figure 3 shows the preparation of compounds represented by Structural Formula (I). In Figure 3, a reductive amination may be carried out with reducing 20 regents such as sodium cyanoborohydride, sodium acetoxyborohydride or sodium borohydride in a solvent such as methanol, ethanol, tetrahydrofuran (THF), dichloromethane or dichloroethane at room temperature up to the reflux temperature for the solvent used for 5 minutes 25 to 72 h.

Figure 4 shows the preparation of representative compounds represented of Structural Formula (I), wherein Ar¹ and/or Ar² can be substituted with R⁴⁰. In Figure 4, the alkylation reaction may be carried out in a solvent 30 such as acetone, methyl ethyl ketone, ethyl acetate,

-27-

toluene, tetrahydrofuran (THF) or dimethylformamide (DMF) in the presence of a base such as potassium carbonate or sodium hydride and a catalyst such as an alkali metal iodide at room temperature up to the reflux temperature for
5 the solvent used for 5 minutes to 72 h.

Figure 5 is a schematic showing the preparation of representative compounds of Structural Formula (I), wherein Ar¹ and/or Ar² can be substituted with -(O)_u-(CH₂)_t-COOR²⁰, -(O)_u-(CH₂)_t-OC(O)R²⁰, -(O)_u-(CH₂)_t-C(O)-NR²¹R²² or
10 -(O)_u-(CH₂)_t-NHC(O)O-R²⁰. In Figure 5, the hydrolysis reaction may be carried out in a mixture of aqueous alkali metal hydroxide solution and a solvent such as methanol, ethanol, tetrahydrofuran (THF) or dioxane at room temperature up to the reflux temperature for the solvent
15 used for 5 minutes to 72 h. The acylation reaction can be carried out using dicyclohexylcarbodiimide (DCC) or (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (DEC) in a solvent such as tetrahydrofuran (THF), dimethylformamide (DMF) or methylene chloride in the presence of a base such
20 as pyridine or triethylamine (when necessary) at temperatures of 0 to 100°C for 5 minutes to 72 h.

Figure 7 shows the preparation of compounds represented by Structural Formula (I) wherein Ar¹ or Ar² is substituted with R⁴⁰. L4 is a suitable leaving group such
25 as halogen or trifluoromethylsulfonate. In Figure 7, a palladium coupling reaction such as Stille coupling, Suzuki coupling, Heck reaction, or carboxylation using carbon monoxide can be carried out using a palladium catalyst such as tetrakis(triphenylphosphine)palladium,
30 bis(triphenylphosphine)palladium chloride, and palladium

acetate in a solvent such as tetrahydrofuran (THF), 1,4-dioxane, toluene, dimethylformamide (DMF), or dimethylsulfoxide (DMSO) in the presence of additive (when necessary) such as triphenylphosphine, 1,1'-
5 bis(diphenylphosphino)ferrocene, triethylamine, sodium bicarbonate, tetraethylammonium chloride, or lithium chloride at room temperature up to the reflux temperature for the solvent used for 5 minutes to 72 h.

Although Figures 1 - 5 and 7 show the preparation of
10 compounds in which Ar¹ is 3-pyridyl and Ar² is phenyl, analogous compounds with other heteroaryl groups for Ar¹ and/or Ar² can be prepared by using starting materials with heteroaryl groups in the corresponding positions. These starting materials can be prepared according to methods
15 which are known to those of skill in the art.

The invention is illustrated by the following examples which are not intended to be limiting in any way.

EXEMPLIFICATION

Example 1

20 4-(4-Chlorophenyl)-1-[4-(3-methoxyphenyl)-4-(3-pyridinyl)-3-but enyl]piperidin-4-ol

Step 1

To a solution of (3-methoxyphenyl)-(3-pyridinyl)methanone (500mg) in THF (10ml) was added 1.1M
25 cyclopropylmagnesium bromide THF solution (2ml) at 0°C. The reaction mixture was warmed to room temperature, and stirred for 30 minutes. Aqueous ammonium chloride and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous

-29-

sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was filtered and washed with ethyl acetate-hexane (1:2) to give cyclopropyl-(3-methoxyphenyl)-(3-pyridinyl)methanol (470mg).

5 ¹H-NMR (CDCl₃) δ: 0.45-0.59(4H,m), 1.48-1.61(1H,m),
10 3.65(1H,brs), 3.71(3H,s), 6.78(1H,dd), 6.92-7.22(4H,m),
15 7.69(1H,dd), 8.27(1H,dd), 8.55(1H,d).

Step 2

10 To a solution of the product of step 1 (470mg) in acetic acid (5ml) was added 48% aqueous HBr (3ml) at 10°C. The reaction mixture was warmed to room temperature, and stirred for 12 hours. Water and ethyl acetate were added to the reaction mixture and neutralized with dilute NaOH
15 solution. The organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:4) to
20 give 4-bromo-1-(3-methoxyphenyl)-1-(3-pyridinyl)-1-butene (560mg).

15 ¹H-NMR (CDCl₃) δ: 2.66-2.74(2H,m), 3.41-3.46(2H,m),
20 3.67(0.6x3H,s), 3.79(0.4x3H,s), 6.15-6.18(1H,m), 6.73-
25 6.80(3H,m), 7.17-7.47(3H,m), 8.46-8.64(2H,m).

-30-

Step 3

To a solution the product of step 2 (500mg) in DMF (20ml) were added 4-(4-chlorophenyl)-4-hydroxypiperidine (500mg), potassium carbonate (430mg), potassium iodide 5 (130mg) and the mixture was stirred at room temperature for 12 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried with magnesium sulfate. The solvent was distilled off under 10 reduced pressure. The residue was purified by silica gel chromatography eluting with methylene chloride-methanol (10:1) to give the titled compound as major regioisomer (225mg) and minor one (140mg).

Major isomer

15 $^1\text{H-NMR}$ (CDCl_3) δ : 1.65-1.78 (2H, m), 1.98-2.83 (11H, m), 3.79 (3H, s), 6.22 (1H, t), 6.75-6.84 (4H, m), 7.18-7.57 (6H, m), 8.42 (1H, d), 8.50 (1H, dd).

MS m/z: 449 (M+1).

Minor isomer

20 $^1\text{H-NMR}$ (CDCl_3) δ : 1.65-1.79 (2H, m), 2.08-2.88 (11H, m), 3.79 (3H, s), 6.12 (1H, t), 6.68-6.94 (4H, m), 7.15-7.53 (6H, m), 8.40 (1H, dd), 8.53 (1H, d).

MS m/z: 449 (M+1).

-31-

Example 2

4-(4-Chlorophenyl)-1-[4-phenyl-4-(3-pyridinyl)-3-butenyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example 1, but replacing (3-methoxyphenyl)-(3-pyridinyl) methanone with phenyl-(3-pyridinyl) methanone.

Major isomer

¹H-NMR (CDCl₃) δ: 1.67-1.72 (2H, m), 2.07-2.19 (3H, m), 2.31-2.61 (6H, m), 2.75-2.80 (2H, m), 6.18 (1H, t), 7.16-7.48 (11H, m), 8.44 (1H, d), 8.49 (1H, dd).

MS m/z: 419 (M+1).

Minor isomer

¹H-NMR (CDCl₃) δ: 1.69-1.74 (2H, m), 2.18-2.23 (3H, m), 2.43-2.66 (6H, m), 2.82-2.86 (2H, m), 6.18 (1H, t), 7.16-7.48 (11H, m), 8.44 (1H, dd), 8.51 (1H, d).

MS m/z: 419 (M+1).

Example 3

4-(4-Chlorophenyl)-1-[4-(2,5-dimethoxyphenyl)-4-(3-pyridinyl)-3-but enyl]piperidin-4-ol

The titled compound was prepared by following the procedure of example 1, but replacing (3-methoxyphenyl)-(3-pyridinyl) methanone with (2,5-dimethoxyphenyl)-(3-pyridinyl) methanone.

Major isomer

¹H-NMR (CDCl₃) δ: 1.62-1.79 (2H, m), 1.97-2.18 (2H, m), 2.32-2.81 (9H, m) 3.47 (3H, s), 3.79 (3H, s), 5.92 (1H, t), 6.68-6.82 (3H, m), 7.11-7.49 (6H, m), 8.35 (1H, dd), 8.41 (1H, d).

MS m/z: 479 (M+1).

-32-

Minor isomer

¹H-NMR (CDCl₃) δ: 1.62-1.79 (2H, m), 2.01-2.20 (2H, m), 2.28-2.81 (9H, m) 3.49 (3H, s), 3.80 (3H, s), 5.91 (1H, t), 6.70-6.84 (3H, m), 7.12-7.50 (6H, m), 8.35 (1H, dd), 8.41 (1H, d).

5 MS m/z: 479 (M+1).

Example 4

1-[4-(2-Bromo-4-pyridinyl)-4-(3-pyridinyl)-3-butenyl]-4-(4-chlorophenyl)piperidin-4-ol

The titled compound was prepared by following the procedure
10 of example 1, but replacing (3-methoxyphenyl)-(3-pyridinyl)methanone with (2-bromo-4-pyridinyl)-(3-pyridinyl)methanone.

¹H-NMR (CDCl₃) δ: 1.65-1.70 (2H, m), 1.92-2.18 (5H, m), 2.38-2.54 (4H, m), 2.67-2.72 (2H, m), 6.31 (1H, t), 7.14-7.41 (7H, m),
15 8.38-8.41 (2H, m), 8.52 (1H, d), 8.75 (1H, s).

MS m/z: 500 (M+1).

Examples 5-90 and 91-120 can be prepared by the schemes set forth in Figures 1 -5 and 7 and the procedures described above.

20 Example 121

Membrane Preparations for Chemokine Binding and Binding Assays

Membranes were prepared from THP-1 cells (ATCC #TIB202). Cells were harvested by centrifugation, washed twice with
25 PBS (phosphate-buffered saline), and the cell pellets were frozen at -70 to -85°C. The frozen pellet was thawed in ice-cold lysis buffer consisting of 5 mM HEPES (N-2-

-33-

- hydroxyethylpiperazine-N'-2-ethane-sulfonic acid) pH 7.5, 2 mM EDTA (ethylenediaminetetraacetic acid), 5 µg/ml each aprotinin, leupeptin, and chymostatin (protease inhibitors), and 100 µg/ml PMSF (phenyl methane sulfonyl fluoride - also a protease inhibitor), at a concentration of 1 to 5 × 10⁷ cells/ml. This procedure results in cell lysis. The suspension was mixed well to resuspend all of the frozen cell pellet. Nuclei and cell debris were removed by centrifugation of 400 × g for 10 minutes at 4°C.
- 10 The supernatant was transferred to a fresh tube and the membrane fragments were collected by centrifugation at 25,000 × g for 30 minutes at 4°C. The supernatant was aspirated and the pellet was resuspended in freezing buffer consisting of 10 mM HEPES pH 7.5, 300 mM sucrose, 1µg/ml
- 15 each aprotinin, leupeptin, and chymostatin, and 10 µg/ml PMSF (approximately 0.1 ml per each 10⁸ cells). All clumps were resolved using a minihomogenizer, and the total protein concentration was determined using a protein assay kit (Bio-Rad, Hercules, CA, cat #500-0002). The membrane
- 20 solution was then aliquoted and frozen at -70 to -85°C until needed.

Binding Assays - utilized the membranes described above. Membrane protein (2 to 20 µg total membrane protein) was incubated with 0.1 to 0.2 nM ¹²⁵I-labeled RANTES or MIP-1α 25 with or without unlabeled competitor (RANTES or MIP-1α) or various concentrations of compounds. The binding reactions were performed in 60 to 100 µl of a binding buffer consisting of 10 mM HEPES pH 7.2, 1 mM CaCl₂, 5 mM MgCl₂, and 0.5% BSA (bovine serum albumin), for 60 min at room

- 34 -

temperature. The binding reactions were terminated by harvesting the membranes by rapid filtration through glass fiber filters (GF/B or GF/C, Packard) which were presoaked in 0.3% polyethyleneimine. The filters were rinsed with 5 approximately 600 μ l of binding buffer containing 0.5 M NaCl, dried, and the amount of bound radioactivity was determined by scintillation counting in a Topcount beta-plate counter.

The activities of test compounds are reported in the 10 Table below as IC₅₀ values or the inhibitor concentration required for 50% inhibition of specific binding in receptor binding assays using ¹²⁵I-RANTES or ¹²⁵MIP-1 α as ligand and THP-1 cell membranes. Specific binding is defined as the total binding minus the non-specific binding; non-specific 15 binding is the amount of cpm still detected in the presence of excess unlabeled Rantes or ¹²⁵MIP-1 α .

-35-

Table

BIOLOGICAL DATA

<u>Example</u>	<u>IC₅₀ (μM)</u>
1	<1
5	<1
2	<1
3	<1
4	>1


Those skilled in the art will be able to recognize, or
be able to ascertain, using no more than routine
10 experimentation, many equivalents to the specific
embodiments of the invention described herein. Such
equivalents are intended to be encompassed by the following
claims.

-36-

CLAIMS

What is claimed:

1. A method of treating a disease associated with aberrant leukocyte recruitment and/or activation comprising administering to a subject in need thereof an effective amount of a compound represented by the following structural formula:
5



and physiologically acceptable salts thereof, wherein:
10 Ar¹ is a substituted or unsubstituted heteroaryl group;
 Ar² is a substituted or unsubstituted aromatic carbocyclic or heteroaryl group;
 n is an integer from one to about four;
15 M is >NR² or >CR¹R²;
 R¹ is -H, -OH, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH,

-37-

-S-(aliphatic group), -S-(substituted aliphatic group),
-OC(O)-(aliphatic group), -O-C(O)-(substituted
aliphatic group), -CN, -COOH, -CO-NR³R⁴ or -NR³R⁴; and
R² is -H, -OH, an acyl group, a substituted acyl
5 group, -NR⁵R⁶, an aliphatic group, a substituted
aliphatic group, an aromatic group, a substituted
aromatic group, a benzyl group, a substituted benzyl
group, a non-aromatic heterocyclic group or a
substituted non-aromatic heterocyclic group; wherein:
10 R³, R⁴, R⁵ and R⁶ are independently -H, an
aliphatic group, a substituted aliphatic group, an
aromatic group, a substituted aromatic group, a benzyl
group, a substituted benzyl group, a non-aromatic
heterocyclic group or a substituted non-aromatic
15 heterocyclic group; or
R¹ and R², R³ and R⁴, or R⁵ and R⁶ taken together
with the atom to which they are bonded, form a
substituted or unsubstituted non-aromatic heterocyclic
ring.

20 2. The method of Claim 1 wherein:

Ar¹ or Ar² is substituted with -OH, a halogen,
-O-(aliphatic group), -O-(substituted aliphatic group),
-O-(aromatic group), -O-(substituted aromatic group),
an electron withdrawing group, -(O)_u-(CH₂)_t-COOR²⁰,
25 -(O)_u-(CH₂)_t-C(O)-NR²¹R²² or -(O)_u-(CH₂)_t-NHC(O)-O-R²⁰;
wherein:

u is zero or one;

t is an integer from zero to about three;

R^{20} , R^{21} or R^{22} are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or

5 R^{21} and R^{22} , taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.

3. The method of Claim 1 wherein M is $>CR^1R^2$.
4. The method of Claim 3 wherein R^1 is -H or -OH.
- 10 5. The method of Claim 1 wherein R^2 is a substituted or unsubstituted aromatic group.
6. The method of Claim 1 wherein Ar^1 is a substituted or unsubstituted pyridyl group.
7. The method of Claim 1 wherein:
 - 15 Ar^1 is a substituted or unsubstituted 3-pyridyl group; and
 Ar^2 is a substituted or unsubstituted aromatic carbocyclic group or heteroaryl group.
8. The method of Claim 7 wherein:
 - 20 Ar^1 or Ar^2 is substituted with -OH, a halogen, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, $-(O)_u-(CH_2)_v-COOR^{20}$,

-39-

- (O)_u-(CH₂)_t-C(O)-NR²¹R²² or - (O)_u-(CH₂)_t-NHC(O)-O-R²⁰;

wherein:

u is zero or one;

t is an integer from zero to about three;

5 R²⁰, R²¹ or R²² are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or

10 R²¹ and R²², taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.

9. The method of Claim 7 wherein Ar² is a substituted or unsubstituted heteroaryl group

10. The method of Claim 9 wherein M is >CR¹R².

15 11. The method of Claim 10 wherein R² is a substituted or unsubstituted aromatic group.

12. The method of Claim 11 wherein R¹ is -H or -OH; and n is two.

13. The method of Claim 7 wherein Ar² is a substituted or 20 unsubstituted phenyl group.

14. The method of Claim 13 wherein said phenyl group is substituted with -OH, a halogen, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group),

-40-

-O-(substituted aromatic group), an electron withdrawing group, -(O)_u-(CH₂)_t-COOR²⁰, -(O)_u-(CH₂)_t-C(O)-NR²¹R²² or -(O)_u-(CH₂)_t-NHC(O)-O-R²⁰;
wherein:

5 u is zero or one;


t is an integer from zero to about three;

R²⁰, R²¹ or R²² are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or

10 R²¹ and R²², taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.

15 15. The method of Claim 13 wherein said phenyl group bears a meta substituent, R⁴⁰, and the antagonist of chemokine receptor function is represented by the following structural formula:

20



-41-

wherein R⁴⁰ is -OH, halogen, aliphatic group,
-O-(aliphatic group), -O-(substituted aliphatic group),
-O-(aromatic group), -O-(substituted aromatic group),
an electron withdrawing group, -(O)_u-(CH₂)_t-COOR²⁰,
5 -(O)_u-(CH₂)_t-C(O)-NR²¹R²² or -(O)_u-(CH₂)_t-NHC(O)-O-R²⁰;
wherein:


u is zero or one;
t is an integer from zero to about three;
R²⁰, R²¹ or R²² are independently -H, an aliphatic
10 group, a substituted aliphatic group, an aromatic
group, a substituted aromatic group or a non-aromatic
heterocyclic group; or
R²¹ and R²², taken together with the nitrogen atom
to which they are bonded, form a non-aromatic
15 heterocyclic ring.

16. The method of Claim 15 wherein R⁴⁰ is -O-alkyl.

17. The method of Claim 15 wherein:
M is >CR¹R²;
R¹ is -H or -OH;
20 R² is a substituted or unsubstituted aromatic
group; and
n is two.

18. The method of Claim 17 wherein R⁴⁰ is -O-CH₃.

19. A compound represented by the following structural
25 formula:



and physiologically acceptable salts thereof, wherein:

Ar^1 is a substituted or unsubstituted heteroaryl group;

5 Ar^2 is a substituted or unsubstituted aromatic carbocyclic or heteroaryl group;

n is an integer from one to about four;

M is $>\text{NR}^2$ or $>\text{CR}^1\text{R}^2$;

10 R^1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -SH, -S-(aliphatic group), -S-(substituted aliphatic group), -OC(O)-(aliphatic group), -O-C(O)-(substituted aliphatic group), -CN, -COOH, -CO-NR³R⁴ or -NR³R⁴; and

15 R^2 is -H, -OH, an acyl group, a substituted acyl group, -NR⁵R⁶, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; wherein:

20 R³, R⁴, R⁵ and R⁶ are independently -H, an aliphatic group, a substituted aliphatic group, an

-43-

aromatic group, a substituted aromatic group, a benzyl group, a substituted benzyl group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; or

5 R¹ and R², R³ and R⁴, or R⁵ and R⁶ taken together with the atom to which they are bonded, form a substituted or unsubstituted non-aromatic heterocyclic ring.

10 20. The compound of Claim 19 wherein:

Ar¹ or Ar² is substituted with -OH, a halogen, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)_u-(CH₂)_t-COOR²⁰, - (O)_u-(CH₂)_t-C(O)-NR²¹R²² or - (O)_u-(CH₂)_t-NHC(O)-O-R²⁰;

15 wherein:

u is zero or one;

t is an integer from zero to about three;

20 R²⁰, R²¹ or R²² are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or

25 R²¹ and R²², taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.

21. The compound of Claim 19 wherein M is >CR¹R².

22. The compound of Claim 21 wherein R¹ is -H or -OH.

-44-

23. The compound of Claim 19 wherein R² is a substituted or unsubstituted aromatic group.

24. The compound of Claim 19 wherein Ar¹ is a substituted or unsubstituted pyridyl group.

5 25. The compound of Claim 19 wherein:

Ar¹ is a substituted or unsubstituted 3-pyridyl group; and

Ar² is a substituted or unsubstituted aromatic carbocyclic group or heteroaryl group.

10 26. The compound of Claim 25 wherein:

Ar¹ or Ar² is substituted with -OH, a halogen, -O-(aliphatic group), -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)_u-(CH₂)_t-COOR²⁰, - (O)_u-(CH₂)_t-C(O)-NR²¹R²² or -(O)_u-(CH₂)_t-NHC(O)-O-R²⁰; 15 wherein:

u is zero or one;

t is an integer from zero to about three;

20 R²⁰, R²¹ or R²² are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or

25 R²¹ and R²², taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.


27. The compound of Claim 25 wherein Ar² is a substituted or unsubstituted heteroaryl group.

-45-

28. The compound of Claim 27 wherein M is $>CR^1R^2$.
29. The compound of Claim 28 wherein R² is a substituted or unsubstituted aromatic group.
30. The compound of Claim 29 wherein R¹ is -H or -OH; and
5 n is two.
31. The compound of Claim 25 wherein Ar² is a substituted or unsubstituted phenyl group.
32. The compound of Claim 31 wherein said phenyl group is substituted with -OH, a halogen, -O-(aliphatic group),
10 -O-(substituted aliphatic group), -O-(aromatic group), -O-(substituted aromatic group), an electron withdrawing group, -(O)_u-(CH₂)_t-COOR²⁰, -(O)_u-(CH₂)_t-C(O)-NR²¹R²² or -(O)_u-(CH₂)_t-NHC(O)-O-R²⁰; wherein:
15 u is zero or one;
t is an integer from zero to about three;
R²⁰, R²¹ or R²² are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group; or
20 R²¹ and R²², taken together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring.
33. The compound of Claim 31 wherein said phenyl group bears a meta substituent, R⁴⁰, and the antagonist of
25

-46-

chemokine receptor function is represented by the following structural formula:



wherein R^{40} is -OH, halogen, aliphatic group,
 5 substituted aliphatic group, -O-(aliphatic group),
 -O-(substituted aliphatic group), -O-(aromatic group),
 -O-(substituted aromatic group), an electron
 withdrawing group, -(O)_u-(CH₂)_t-COOR²⁰,
 -(O)_u-(CH₂)_t-C(O)-NR²¹R²² or -(O)_u-(CH₂)_t-NHC(O)-O-R²⁰;
 10 wherein:
 u is zero or one;
 t is an integer from zero to about three;
 R²⁰, R²¹ or R²² are independently -H, an aliphatic
 group, a substituted aliphatic group, an aromatic
 group, a substituted aromatic group or a non-aromatic
 heterocyclic group; or
 15 R²¹ and R²², taken together with the nitrogen atom
 to which they are bonded, form a non-aromatic
 heterocyclic ring.

-47-

34. The compound of Claim 33 wherein R⁴⁰ is -O-alkyl.

35. The compound of Claim 33 wherein:

M is >CR¹R²;

R¹ is -H or -OH;

5 R² is a substituted or unsubstituted aromatic
group; and
n is two.

36. The compound of Claim 35 wherein R⁴⁰ is -O-CH₃.

37. A method of antagonizing a chemokine receptor in a
10 mammal in need thereof comprising administering a
compound of Claim 19.

1/16




Figure 1

2/16




Figure 2

3/16




Figure 3

4/16




Figure 4

5/16




Figure 5

6/16




Figure 6A

7/16




Figure 6B

8/16






Figure 6C


9/16




Example 39




Example 40




Example 41




Example 42




Example 43




Example 44




Example 45




Example 46




Example 47




Example 48




Example 49



Example 50



Example 51



Example 52

Figure 6D

10/16




Figure 6E

11/16






Figure 6F


12/16




Example 81




Example 82




Example 83




Example 84




Example 85




Example 86




Example 87



Example 88



Example 89



Example 90

Figure 6G

13/16




Figure 6H

14/16




Figure 6I

15/16













Figure 6J

16/16




Figure 7

INTERNATIONAL SEARCH REPORT

Ir Application No
PCT/99/01365

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6	C07D401/06	C07D401/14	C07D409/14	C07D405/14	C07D213/38
	C07D471/10	C07D491/10	C07D495/10	A61K31/44	

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 931 450 A (SONNEWALD URSULA) 5 June 1990 see claims 1,11; examples ---	19
X	DATABASE WPI Section Ch, Week 8128 Derwent Publications Ltd., London, GB; Class B03, AN 81-507850 XP002103024 & JP 56 061373 A (HOKURIKU PHARM CO LTD) , 26 May 1981 see abstract ---	19
X	DE 28 00 535 A (DEGUSSA) 13 July 1978 see claim 1; table 2 ---	19
X	DE 24 31 178 A (CERMOL SA) 16 January 1975 see example 9 ---	19
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

18 May 1999

Date of mailing of the international search report

27/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

In	International Application No
PCT	99/01365

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 21 62 802 A (PFIZER CORP.) 21 September 1972 see claims 1,10 ---	19
X	FR 1 462 206 A (INNOTHERA) 16 December 1966 see example 24 ---	19
X	US 2 712 020 A (BURROUGHS WELLCOME & CO.) 28 June 1955 see claim 1; examples 4,6 ---	19
X	US 3 238 216 A (JANSSEN N.V.) 1 March 1966 see column 52 - column 57; claims ---	19
A	WO 97 44329 A (SHIOTA ET AL.) 27 November 1997 see the whole document -----	1,37

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/01365

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-18, 37
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-18, 37
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP/99/01365

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 4931450	A 05-06-1990	AT 95518 T AU 600248 B AU 6719387 A CA 1297105 A DE 3787657 D DE 3787657 T DK 3887 A, B, EP 0231996 A ES 2059360 T FI 870059 A, B, IE 62180 B JP 2061927 C JP 7091289 B JP 62228073 A PT 84064 A, B		15-10-1993 09-08-1990 09-07-1987 10-03-1992 11-11-1993 03-02-1994 17-09-1987 12-08-1987 16-11-1994 08-07-1987 28-12-1994 10-06-1996 04-10-1995 06-10-1987 01-02-1987
DE 2800535	A 13-07-1978	GB 1597591 A AR 227866 A AT 362355 B AT 18978 A AT 362356 B AT 707379 A AU 522750 B AU 3239278 A BE 862800 A CA 1096380 A CA 1132139 A DD 136265 A DD 142883 A DK 12478 A FI 780083 A FR 2377396 A FR 2382449 A IN 147465 A IN 149408 A JP 53101362 A NL 7800350 A SE 7800326 A US 4254269 A US 4281010 A US 4206213 A ZA 7800174 A		09-09-1981 30-12-1982 11-05-1981 15-10-1980 11-05-1981 15-10-1980 24-06-1982 19-07-1979 10-07-1978 24-02-1981 21-09-1982 27-06-1979 16-07-1980 13-07-1978 13-07-1978 11-08-1978 29-09-1978 08-03-1980 28-11-1981 04-09-1978 14-07-1978 13-07-1978 03-03-1981 28-07-1981 03-06-1980 29-11-1978
DE 2431178	A 16-01-1975	CH 585209 A CH 583713 A AR 203031 A AT 340932 B AT 539374 A BE 816984 A CA 1025452 A DK 348374 A FI 199674 A FR 2234898 A GB 1461689 A JP 1311667 C JP 50036480 A JP 60037095 B NL 7408507 A, B,		28-02-1977 14-01-1977 08-08-1975 10-01-1978 15-05-1977 16-10-1974 31-01-1977 21-04-1975 30-12-1974 24-01-1975 19-01-1977 11-04-1986 05-04-1975 24-08-1985 31-12-1974

INTERNATIONAL SEARCH REPORT

Information on patent family members

In national Application No

PCT/US99/01365

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
DE 2431178 A		SE US	7408344 A 3940386 A	30-12-1974 24-02-1976
DE 2162802 A	21-09-1972	AU AU BE CH CH CH FR GB	465190 B 3761772 A 777849 A 555357 A 540880 A 543476 A 2121719 A 1320481 A	18-09-1975 12-07-1973 07-07-1972 31-10-1974 15-10-1973 14-12-1973 25-08-1972 13-06-1973
FR 1462206 A	22-02-1967	NONE		
US 2712020 A	28-06-1955	NONE		
US 3238216 A	01-03-1966	NONE		
WO 9744329 A	27-11-1997	JP AU EP	9309877 A 3135497 A 0914319 A	02-12-1997 09-12-1997 12-05-1999